Article Text

Download PDFPDF
Randomised controlled trial
The quadrivalent HPV vaccine is effective prophylaxis against HPV-related external genital lesions in young men
  1. Basil Donovan1,
  2. Andrew E Grulich1
  1. 1Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia
  1. Correspondence to Basil Donovan
    Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia;bdonovan{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMed.


Awareness is growing that in developed countries around a quarter of human papillomavirus (HPV) related cancers occur in men and that the incidence of some of those cancers, particularly anal cancers1 and certain oropharyngeal cancers,2 is growing. As well as providing direct protection for males, a population-based programme of male HPV vaccination could provide protection for females where the levels of population coverage of female vaccination programmes are limited. There has been no formal evaluation of the efficacy of the HPV vaccination against HPV-related disease in males.


This rigorous randomised, placebo-controlled, double-blind study enrolled 4065 boys and men aged 16–26 years through 71 sites in 18 countries. None was permitted to have had more than five sexual partners in their lives, and boys …

View Full Text


  • Competing interests BD and AEG have received honoraria and research funding from CSL Biotherapies. BD has also received honoraria from Sanofi Pasteur MSD.